We confirmed the contribution of PNPLA3, MBOAT7, and TM6SF2 loss-of-function variants to mitochondrial dysfunction that features progressive MASLD, suggesting that their restoration which reverses the failure phenotype may be a successful therapeutic strategy. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.